Last reviewed · How we verify

NCT06948487

Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis

Recruiting now Last updated 17 July 2025
What this trial tests

trial in Gastritis in 12,000 participants. Currently enrolling.

Timeline
17 June 2025
Primary endpoint
30 November 2025
3 June 2027

Quick facts

Lead sponsorDaewoong Pharmaceutical Co. LTD.
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment12,000
Start date17 June 2025
Primary completion30 November 2025
Estimated completion3 June 2027
Sites1 location across South Korea

Conditions studied

Sponsor

Daewoong Pharmaceutical Co. LTD. — full company profile →

Who can join

Adults 19 to 75, any sex, with Gastritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastritis

Currently open trials in the same condition.

Other Daewoong Pharmaceutical Co. LTD. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06948487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing